This peer was Novo Nordisk, which like Eli Lilly sells a popular drug approved specifically for obesity. Eli Lilly's recent ...

Danish drugmaker Novo Nordisk's stock was down nearly 20% in premarket trading Tuesday morning after the company cut its ...

Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 4.3% in the morning session after its key competitor in the ...

Eli Lilly stock slips after Novo Nordisk trims 2025 forecast; Jaypirca meets endpoint in CLL trial against J&J's Imbruvica, ...

Eli Lilly said on Tuesday its drug for a type of blood cancer was more effective in a head-to-head study against AbbVie's ...

Shares in Novo Nordisk fell as much as 30% after it slashed sales and profits forecasts for the second time this year amid ...

Eli Lilly and Company (LLY) on Tuesday said that its cancer drug Jaypirca was more effective than AbbVie’s drug Imbruvica in ...

Eli Lilly & Company (NYSE:LLY) ranks among the stocks to benefit from an onshoring boom. On July 22, BMO Capital reaffirmed ...

Shares of Novo Nordisk (NVO) are down 25% after the European pharmaceutical giant lowered its full-year sales and profit ...

Eli Lilly's biggest growth driver, tirzepatide, will continue facing scrutiny from investors and analysts. The company's oral ...

The newest BTK inhibitor on the market, Eli Lilly’s Jaypirca, has s | In a phase 3 trial, the newest Bruton’s tyrosine kinase ...

Eli Lilly's acquisition of Vere Therapeutics promises to revolutionize cardiovascular care with innovative one-time gene ...